GenSight Biologics S A : CORPORATE PRESENTATION-SEPTEMBER 2023

Corporate Presentation

September 2023

A LEADING Gene Therapy BIOTECHNOLOGY COMPANY

GENSIGHT-BIOLOGICS.COM

Disclaimer

This document contains forward-looking statements and estimates made by the GenSight Biologics S.A. (the "Company"), including with respect to the anticipated future performance of the Company, its subsidiaries and affiliates, and the market in which they operate. They include all matters that are not historical facts. These forward-looking statements can be identified by the use of forward-looking terminology including the terms "developments," "estimates," "expects," "intends," "may," "milestones," "potential," "value," "time to market," "targeting," "on track," "planned," "will," "move to," or other variations or comparable terminology, or by discussions of strategy and funding, as well as the Company's, its subsidiaries' and affiliates' technology, and are based on financial and non-financial information, including projections as to the future regulatory situation and other information and assumptions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may

depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of the Company, its subsidiaries and affiliates or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Forward-looking statements, forecasts and estimates only speak as of the date of this forward-looking statement, and no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. The Company, its subsidiaries and affiliates disclaim any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any events, or changes in conditions or circumstances on which any such statement, forecast or estimate is based.

2 September 2023 - non confidential

Investment Case - Transitioning from R&D to Commercial Organization

1

2

3

4

5

Late-stage Biotech

company

Seasoned

management team / Solid investor base

LUMEVOQ®

Strong clinical data in

LHON

LUMEVOQ®

Defining registration

pathway

Cutting edge optogenetics in Retinitis Pigmentosa

Public company founded in 2012 dedicated to developing and commercializing gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system.

Euronext Listed SIGHT

Management team with strong and highly relevant Biotech experience in R&D and commercialization

Solid investor base of Healthcare specialist investors, including US based investors.

LUMEVOQ® completed 3 Phase III studies in Leber Hereditary Optic Neuropathy (ND4 LHON), a rare and highly debilitating genetic ophthalmic disease leading to sudden loss of central vision and affecting c. 1,200 - 1,500 new patients / year in Europe and the US

Available in France through paid Early Access at €700,000 for a bilateral injection (currently paused pending product availability in Q1 2024)

Ongoing discussion with EMA and US FDA to confirm registration pathway

GS030 outstanding early findings reporting blind patients to precisely identify objects (published in Nature Medicine in May 21)

Extension cohort currently being recruited, expected to be completed by year end 2023

3 April 2023 - non confidential

Seasoned Executive Team

Bernard Gilly

Chief Executive Officer

PIXIUM VISION (Since 2011) FOVEA PHARMA (2005-2009) SOFINNOVA PARTNERS (2000-2005) TRANSGENE (1992-2000)

Ph.D. in biology and bio-economics

Thomas Gidoin	Magali Taiel
Chief Financial Officer	Chief Medical Officer
DBV TECHNOLOGIES (2012-2015)	ProQR THERAPEUTICS (2016-2018)
IPSEN (2008-2011)	ELI LILLY (2004-2016)
ERNST & YOUNG (2007-2008)	PFIZER (2001-2004)
	SERVIER (1999-2001)
	M.D., Board-certified ophthalmologist

Scott Jeffers	Philippe Motté
Chief Technical Officer	SVP, Regulatory & Quality

	REDPIN THERAPEUTICS (2021-2022)	GENFIT (2020-2022)
	UNIQURE (2019-2021)	MEDDAY (2019-2020)
	SELECTA BIOSCIENCES (2018-2019)	ABBVIE (2013-2018)
	BRAMMER BIO (2015-2018)	IPSEN (2004-2013)
	Ph.D. in virology	ROCHE (1998-2004)
		GSK (1991-1998)
		SANOFI (1989-1991)
4	September 2023 - non confidential	Pharm.D. & Ph.D. in human biology

Pipeline: solid and advanced product portfolio in ophthalmic Gene Therapy

MTS Platform

LHON ND4 (EU)

EMA Orphan Drug Designation

LHON ND4 (US)

FDA Orphan Drug Designation

GS011 LHON ND1

New Undisclosed

Optogenetics

GS030	Retinitis Pigmentosa (RP)
EMA & FDA Orphan Drug Designation

GS030	Dry AMD &
Geographic Atrophy

				Expected
Preclinical	Phase I / II	Phase III	Registration	Approval	Market Opportunity

*	~ 450 new patients per year

~ 250 new patients per year

~ 100 new patients per year

~ 1,500 new patients per year

* Following the withdrawal of the EMA application, GenSight is assessing next steps with the EMA

2025	~ 15-20,000 new patients per year
	~ 350-400,000 new patients per year

5 September 2023 - non confidential